Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2003 Dec;17(6):1435-48, ix.

Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.

Author information

  • 1Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104, USA. arook@mail.med.upenn.edu

Abstract

It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and S├ęzary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeutics is based upon the exceedingly important role of the host immune response in effecting progression of disease. In this article we discuss the data that support the importance of the host immune response in the control of progression of CTCL and the role that cytokine therapy has in supporting the host immune response and the effects of this approach to induce regression of skin and systemic disease.

PMID:
14710894
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk